

## Special Issue

# Gene Therapy with Emphasis on RNA Interference

### Message from the Guest Editor

The progress in gene therapy has been hampered by delivery inefficacy and safety concerns. Recent progress has casted some promising light on future development. A number of viral vectors have been re-engineered for improved delivery and enhanced safety. In this context, adenovirus, adeno-associated virus, lentivirus, retroviruses and other virus vectors have provided therapeutic efficacy for various diseases such as severe combined immunodeficiency, hemophilia, cancer and infectious diseases. The discovery of RNA interference, particularly the use of short interfering RNA and micro-RNA for reversible gene silencing, has substantially widened the application range of gene therapy. In this Special Issue, applications of various viral vectors and their use in gene therapy are reviewed with a special emphasis on RNA interference.

---

### Guest Editor

Dr. Kenneth Lundstrom  
PanTherapeutics, Rue des Remparts 4, CH-1095 Lutry, Switzerland

---

### Deadline for manuscript submissions

closed (28 February 2015)



## Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/3723](http://mdpi.com/si/3723)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/](http://mdpi.com/journal/)

[viruses](http://viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).